<DOC>
	<DOC>NCT00973245</DOC>
	<brief_summary>This is an exploratory investigation of safety, pharmacokinetic (PK) and pharmacodynamic (PD) effects of BAY59-7939 with multiple oral doses of 10 mg, 15 mg and 20 mg once daily (od) in Japanese subjects with non-valvular atrial fibrillation (originally described in Japanese).</brief_summary>
	<brief_title>BAY59-7939 in Atrial Fibrillation Once Daily (OD)</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Japanese subjects with nonvalvular AF who met all of the following criteria: Male subjects aged 20 years or older and postmenopausal female subjects Subjects with persistent or paroxysmal nonvalvular AF with &gt;/=2 episodes before enrollment, at least 1 of which had been verified by ECG recording within 4 weeks before randomization Subjects who were at risk for stroke as follows: Subjects with at least one risk factor for thromboembolism (hypertension, diabetes mellitus, coronary artery disease, congestive heart failure). Subjects aged 60 years old and above regardless of the existence of above risk factors. History or presence of stroke or transient ischemic attack. History of intracerebral hemorrhage. History or presence of bleeding at randomization; intraocular or gastrointestinal bleeding within the last 6 months prior to randomization.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>BAY59-7939</keyword>
	<keyword>Rivaroxaban</keyword>
	<keyword>Non-valvular atrial fibrillation</keyword>
	<keyword>Japanese Patients</keyword>
	<keyword>Phase II</keyword>
</DOC>